Current clinical management of patients with glioblastoma.
Cancer Rep (Hoboken)
; 2(6): e1216, 2019 12.
Article
en En
| MEDLINE
| ID: mdl-32721125
ABSTRACT
BACKGROUND:
Glioblastoma (GB) is the most aggressive primary brain tumor, historically resistant to treatment, and with overall fatal outcome. RECENTFINDINGS:
Recently, several molecular subgroups and rare genetic alterations have been described in GB. In this review article, we will describe the current clinical management of patients with GB in the United States, discuss selected next-generation molecular-targeted therapies in GB, and present ongoing clinical trials for patients with GB. This review is intended for clinical and preclinical researchers who conduct work on GB and would like to understand more about the current standard of treatment of GB patients, historical perspectives, current challenges, and ongoing and upcoming clinical trials.CONCLUSIONS:
GB is an extremely complex disease, and despite recent progress and advanced therapeutic strategies, the overall patient's prognosis remains dismal. Innovative strategies and integrative ways of approach to disease are urgently needed.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Glioblastoma
/
Procedimientos Neuroquirúrgicos
/
Quimioradioterapia
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Cancer Rep (Hoboken)
Año:
2019
Tipo del documento:
Article